Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD. 

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.

Avoidance of prostate cancer screening linked to increased risk of PCSM

Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

"If you determine you can invest in a volatile environment, the best approach is to do so over a period of time," writes Jeff Witz, CFP.

Money Matters: How to cope with market volatility in 2025

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Exploring Novel Delivery Systems to Advance NMIBC Treatment

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.

Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Video content above is prompted by the following: 

How easily can TAR-200 and other emerging delivery systems be adopted into clinical practice for the treatment of NMIBC?

What are your thoughts on the future outlook for NMIBC?

Videos

Karim Chamie, MD, MSHS, discusses how innovative non–muscle invasive bladder cancer (NMIBC) delivery systems such as TAR-200 offer targeted, less toxic treatment options, showing promise for high-risk patients with improved efficacy and patient tolerance through localized drug administration.

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced targeted technologies. Current research focuses on innovative platforms such as nanoparticle carriers, thermosensitive hydrogels, and personalized molecular delivery mechanisms to improve therapeutic efficacy and minimize systemic toxicity.

Drug Delivery Systems in NMIBC

An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.

TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.


Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

EP: 1.Drug Delivery Systems in NMIBC

EP: 2.TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

EP: 3.Adoption of Emerging Delivery Systems and Future Outlook for NMIBC